• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    GeneDx Holdings (WGS) Could Be 26% Undervalued Following Long Read Genome Push

    Simply Wall St·10/23/2026 13:44:15
    Listen to the news

    GeneDx Holdings (WGS) is back in focus after rolling out plans to add long-read whole genome sequencing and highlighting 27 scientific abstracts accepted for the ASHG 2026 genetics conference.

    Against that product backdrop, GeneDx Holdings has faced a sharp pullback in recent weeks, with the share price down 26.1% over the past month and 49.3% year to date to US$67.14. This comes even though the 90 day share price return is up 13.6% and the three year total shareholder return is very large, signalling long term holders have still seen substantial gains while near term momentum has cooled as the market reassesses both growth potential and risk around the story.

    Scan beyond GeneDx Holdings and size up other genomics and healthcare AI players on our hand picked screen of 36 healthcare AI stocks that are also pushing the boundaries of data driven medicine.

    GeneDx now sits at the crossroads of a sharp pullback and upbeat product news, with bulls pointing to progress and bears pointing to losses. Which story does the valuation argue for next?

    Most Popular Narrative: 26% Undervalued

    At a last close of $67.14 against an implied fair value of about $90.44, the most followed GeneDx Holdings narrative frames the recent pullback as a discount, while still stressing that execution on pediatrics and AI driven genomics remains central to the story.

    Rapid expansion into new and underpenetrated markets including general pediatrics (driven by American Academy of Pediatrics guidelines), NICU, and additional pediatric specialties positions GeneDx for substantial future volume and revenue growth as adoption of genomics as a frontline diagnostic tool accelerates.

    Scaling proprietary AI powered genomic interpretation platforms and integrating newly acquired Fabric Genomics technology enhances efficiency and accuracy, which should both lower per sample costs and support margin expansion as the business grows.

    See why 26 investors see GeneDx Holdings as 26% undervalued.

    Result: Fair Value of $90.44 (UNDERVALUED)

    Still, the GeneDx narrative can break if reimbursement tightens or pediatric adoption moves more slowly than analysts expect, putting those fair value assumptions under real pressure.

    Find out about the key risks to this GeneDx Holdings narrative.

    Another View: GeneDx Holdings Looks Expensive On Sales

    Price targets and fair value models point to upside for GeneDx Holdings, yet the simple P/S check tells a tougher story. At 4.4x sales, the stock trades well above the US Healthcare sector on 1.3x and peers on 1.5x, and even slightly ahead of its own 4.3x fair ratio.

    That kind of premium can reward you if growth and profitability arrive as expected. It also raises the risk that any stumble in execution or sentiment forces the multiple back toward that fair ratio level.

    See what the numbers say about this price in our valuation breakdown, then decide which story you think the market is more likely to move toward next See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:WGS P/S Ratio as at Oct 2026
    NasdaqGS:WGS P/S Ratio as at Oct 2026

    Next Steps

    Mixed message or clear signal? Either way, this is a moment to move fast, stress test the numbers yourself and decide where GeneDx Holdings really fits in your portfolio. Then weigh those potential upsides in the context of 3 key rewards

    Looking for more GeneDx investment ideas?

    If GeneDx Holdings is already on your radar, do not stop there. Broaden your opportunity set and let structured stock ideas do some of the heavy lifting.